Particulate delivery systems for biodefense subunit vaccines

Advanced Drug Delivery Reviews

Volumn 57, Issue 9, 2005, Pages 1247-1265

  Bramwell, Vincent W ^a   Eyles, Jim E ^b   Alpar, H Oya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Anthrax; Biowarfare; Botulinum toxin; Filovirus; Liposome; Plague; PLGA; Polylactide; Smallpox; Subunit; Vaccine

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BIODEGRADATION; BIOTECHNOLOGY; CELLS; MEDICAL PROBLEMS; PARTICLES (PARTICULATE MATTER); POLYMERS;

ANIMAL MODELS; BIODEFENSE; PARTICULATE DELIVERY SYSTEMS; SMALLPOX;

VACCINES;

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BACTERIAL ANTIGEN; BOTULINUM F TOXOID; BOTUMINK; CIDOFOVIR; COPOLYMER; EBOLA VACCINE; EQUINE EBOLA IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIPID A; LIPOSOME; LIVE VACCINE; MATRIX PROTEIN; MICROSPHERE; PLAGUE VACCINE; PLAGUE VACCINE USP; POLYGLACTIN; POLYLACTIDE; POLYMER; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; RICIN TOXOID; SMALLPOX VACCINE; SUBUNIT VACCINE; THIOMERSAL; UNCLASSIFIED DRUG; VACCINE; VIRULENCE ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; YERSINIA PESTIS VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; BOTULISM; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DRUG DELIVERY SYSTEM; DRUG SAFETY; FILOVIRUS; HEALTH CARE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MICROENCAPSULATION; NONHUMAN; ORTHOPOXVIRUS; PLAGUE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMALLPOX; VIRUS HEMORRHAGIC FEVER; YERSINIA PESTIS;

ANIMALS; ANTHRAX; BACTERIAL VACCINES; BIOCOMPATIBLE MATERIALS; BIOLOGICAL WARFARE; BOTULISM; CHEMICAL WARFARE AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; LIPOSOMES; PLAGUE; POLYGLYCOLIC ACID; POLYMERS; RICIN; SMALLPOX; VIRAL VACCINES;

EID: 20344381302     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.01.010     Document Type: Review

References (115)

1. S. Liljeqvist, and S. Stahl Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines J. Biotechnol. 73 1999 1 33
2. H. Engers, M.P. Kieny, P. Malhotra, and J.R. Pink Third meeting on novel adjuvants currently in or close to clinical testing Vaccine 21 2003 3503 3524
3. R.K. Gupta, and G.R. Siber Adjuvants for human vaccines-current status, problems and future prospects Vaccine 13 1995 1263 1276
4. R.K. Gupta Aluminum compounds as vaccine adjuvants Adv. Drug Deliv. Rev. 32 1998 155 172
5. J.C. Cox, and A.R. Coulter Adjuvants-a classification and review of their modes of action Vaccine 15 1997 248 256
6. R.K. Gherardi, M. Coquet, P. Cherin, L. Belec, P. Moretto, P.A. Dreyfus, J.F. Pellissier, P. Chariot, and F.J. Authier Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle Brain 124 2001 1821 1831
7. R.K. Gherardi Lessons from macrophagic myofasciitis: Towards definition of a vaccine adjuvant-related syndrome Rev. Neurol. (Paris) 159 2003 162 164
8. Q. Vu, K.M. McCarthy, J.M. McCormack, and E.E. Schneeberger Lung dendritic cells are primed by inhaled particulate antigens, and retain MHC class II/antigenic peptide complexes in hilar lymph nodes for a prolonged period of time Immunology 105 2002 488 498
9. K.D. Newman, P. Elamanchili, G.S. Kwon, and J. Samuel Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo J. Biomed. Materi. Res. 60 2002 480 486
10. L. Vidard, M. Kovacsovics-Bankowski, S.K. Kraeft, L.B. Chen, B. Benacerraf, and K.L. Rock Analysis of MHC class II presentation of particulate antigens of B lymphocytes J. Immunol. 156 1996 2809 2818
11. H.F. Sun, K.G.J. Pollock, and J.M. Brewer Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro Vaccine 21 2003 849 855
12. J. Nugent, A.L.W. Po, and E.M. Scott Design and delivery of non-parenteral vaccines J. Clin. Pharm. Ther. 23 1998 257 285
13. D.T. O'Hagan, M. Singh, and R.K. Gupta Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines Adv. Drug Deliv. Rev. 32 1998 225 246
14. P.B. Odonnell, and J.W. McGinity Properties of multiphase microspheres of poly(dl-lactic acid) or poly(dl-lactic-co-glycolic acid) produced by mechanical agitation, sonication, or potentiometric dispersion J. Microencapsul. 13 1996 667 677
15. R. Audran, K. Peter, J. Dannull, Y. Men, E. Scandella, M. Groettrup, B. Gander, and G. Corradin Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro Vaccine 21 2003 1250 1255
16. M. Rao, S.W. Rothwell, N.M. Wassef, R.E. Pagano, and C.R. Alving Visualization of peptides derived from liposome-encapsulated proteins in the trans-golgi area of macrophages Immunol. Lett. 59 1997 99 105
17. R.D. Perry, and J.D. Fetherston Yersinia pestis-etiologic agent of plague Clin. Microbiol. Rev. 10 1997 35 66
18. R.A. Smego, J. Frean, and H.J. Koornhof Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections Eur. J. Clin. Microbiol. Infect. Dis. 18 1999 1 15
19. E.D. Williamson Plague vaccine research and development J. Appl. Microbiol. 91 2001 606 608
20. P. Russell, S.M. Eley, S.E. Hibbs, R.J. Manchee, A.J. Stagg, and R.W. Titball A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model Vaccine 13 1995 1551 1556
21. E.E. Baker, H. Sommer, L.E. Foster, E. Meyer, and K.F. Meyer Studies on immunization against plague: I. The isolation and characterization of the soluble antigen of Pasteurella pestis J. Immunol. 68 1952 131 145
22. S.B. Price, K.Y. Leung, S.S. Barve, and S.C. Straley Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis J. Bacteriol. 171 1989 5646 5653
23. 2+ response virulence genes J. Bacteriol. 173 1991 2649 2657
24. S.B. Price, M.D. Freeman, and K.S. Yeh Transcriptional analysis of the Yersinia pestis pH 6 antigen gene J. Bacteriol. 177 1995 5997 6000
25. 2+ in Yersinia pestis include structural genes for outer membrane proteins Infect. Immun. 51 1986 445 454
26. S.E.C. Leary, E.D. Williamson, K.F. Griffin, P. Russell, S.M. Eley, and R.W. Titball Active immunization with recombinant V-antigen from Yersinia pestis protects mice against plague Infect. Immun. 63 1995 2854 2858
27. E.D. Williamson, and R.W. Titball Vaccines against dangerous pathogens Br. Med. Bull. 62 2002 163 173
28. E.D. Williamson, S.M. Eley, A.J. Stagg, M. Green, P. Russell, and R.W. Titball A single dose sub-unit vaccine protects against pneumonic plague Vaccine 19 2000 566 571
29. E.D. Williamson, S.M. Eley, A.J. Stagg, M. Green, P. Russell, and R.W. Titball A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague Vaccine 15 1997 1079 1084
30. E.D. Williamson, S.M. Eley, K.F. Griffin, M. Green, P. Russell, S.E.C. Leary, P.C.F. Oyston, T. Easterbrook, K.M. Reddin, A. Robinson, and R.W. Titball A new improved subunit vaccine for plague-the basis of protection FEMS Immunol. Med. Microbiol. 12 1995 223 230
31. J.M. Anderson, and M.S. Shive Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 1997 5 24
32. J. Cox, and A. Coulter Prospects for the development of new vaccine adjuvants BioDrugs 12 1999 439 453
33. E.D. Williamson, G.J.E. Sharp, S.M. Eley, P.M. Vesey, T.C. Pepper, R.W. Titball, and H.O. Alpar Local and systemic immune response to a microencapsulated sub-unit vaccine for plague Vaccine 14 1996 1613 1619
34. J.E. Eyles, E.D. Williamson, I.D. Spiers, A.J. Stagg, S.M. Jones, and H.O. Alpar Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits J. Control. Release 63 2000 191 200
35. J.E. Eyles, I.D. Spiers, E. Diane Williamson, and H. Oya Alpar Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines Vaccine 16 1998 2000 2009
36. M.E. Baca-Estrada, M.M. Foldvari, M.M. Snider, K.K. Harding, B.B. Kournikakis, L.A. Babiuk, and P.P. Griebel Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses Vaccine 18 2000 2203 2211
37. K.M. Reddin, T.J. Easterbrook, S.M. Eley, P. Russell, V.A. Mobsby, D.H. Jones, G.H. Farrar, E. Diane Williamson, and A. Robinson Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis Vaccine 16 1998 761 767
38. C. Kirby, and G. Gregoriadis Dehydration-rehydration vesicles-a simple method for high-yield drug entrapment in liposomes Biotechnology 2 1984 979 984
39. D.N. Kyriacou, A.C. Stein, P.R. Yarnold, D.M. Courtney, R.R. Nelson, G.A. Noskin, J.A. Handler, and R.R. Frerichs Clinical predictors of bioterrorism-related inhalational anthrax Lancet 364 2004 449 452
40. L. Baillie The development of new vaccines against Bacillus anthracis J. Appl. Microbiol. 91 2001 609 613
41. B.W. McBride, A. Mogg, J.L. Telfer, M.S. Lever, J. Miller, P.C.B. Turnbull, and L. Baillie Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers Vaccine 16 1998 810 817
42. J.D. Grabenstein Anthrax vaccine: a review Immunol. Allergy Clin. North Am. 23 2003 713 730
43. G.P. Gladstone Protective antigen present in cell-free culture filtrates Br. J. Exp. Pathol. 27 1946 349 418
44. S. Reuveny, M.D. White, Y.Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan Search for correlates of protective immunity conferred by anthrax vaccine Infect. Immun. 69 2001 2888 2893
45. S. Welkos, S. Little, A. Friedlander, D. Fritz, and P. Fellows The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores Microbiology 147 2001 1677 1685
46. H. Marcus, R. Danieli, E. Epstein, B. Velan, A. Shafferman, and S. Reuveny Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine Infect. Immun. 72 2004 3471 3477
47. H.C. Flick-Smith, J.E. Eyles, R. Hebdon, E.L. Waters, R.J. Beedham, T.J. Stagg, J. Miller, H.O. Alpar, L.W.J. Baillie, and E.D. Williamson Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice Infect. Immun. 70 2002 2022 2028
48. G.E. Rhie, M.H. Roehrl, M. Mourez, R.J. Collier, J.J. Mekalanos, and J.Y. Wang A dually active anthrax vaccine that confers protection against both bacilli and toxins Proc. Natl. Acad. Sci. U. S. A. 100 2003 10925 10930
49. J.L. Middlebrook, and R.B. Dorland Bacterial toxins: cellular mechanisms of action Microbiol. Rev. 48 1984 199 221
50. S. Bavari, D.D. Pless, E.R. Torres, F.J. Lebeda, and M.A. Olson Identifying the principal protective antigenic determinants of type A botulinum neurotoxin Vaccine 16 1998 1850 1856
51. L.L. Simpson Identification of the major steps in botulinum toxin action Annu. Rev. Pharmacol. Toxicol. 44 2004 167 193
52. M.A. Fiock, M.A. Cardella, and N.F. Gearinger Studies on immunity to toxins of Clostridium botulinum: IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxiod J. Immunol. 90 1963 697 702
53. L.S. Siegel Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay J. Clin. Microbiol. 26 1988 2351 2356
54. R.J. Ellis, Immunobiologic agents and drugs available from the centers for disease control: Descriptions, recommendations, adverse reactions, and serologic response, Atlanta, GA: Centers for Disease Control, Public Health Service, US Department of Health and Human Services; 3rd ed., 1982 (Report).
55. L.S. Siegel Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid J. Clin. Microbiol. 27 1989 1906 1908
56. R. Edelman, S.S. Wasserman, S.A. Bodison, J.G. Perry, M. O'Donnoghue, J. DeTolla, and J. Louis Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers Vaccine 21 2003 4335 4347
57. H.F. LaPenotiere, M.A. Clayton, and J.L. Middlebrook Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen Toxicon 33 1995 1383 1386
58. M.A. Clayton, J.M. Clayton, D.R. Brown, and J.L. Middlebrook Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli Infect. Immun. 63 1995 2738 2742
59. M.T. Dertzbaugh, and M.W. West Mapping of protective and cross-reactive domains of the type a neurotoxin of Clostridium botulinum Vaccine 14 1996 1538 1544
60. M.P. Byrne, and L.A. Smith Development of vaccines for prevention of botulism Biochimie 82 2000 955 966
61. K.J. Potter, W. Zhang, L.A. Smith, and M.M. Meagher Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype a, expressed in the methylotrophic yeast Pichia pastoris Protein Expr. Purif. 19 2000 393 402
62. M.P. Byrne, R.W. Titball, J. Holley, and L.A. Smith Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris Protein Expr. Purif. 18 2000 327 337
63. H. Arimitsu, J.C. Lee, Y. Sakaguchi, Y. Hayakawa, M. Hayashi, M. Nakaura, H. Takai, S.N. Lin, M. Mukamoto, T. Murphy, and K. Oguma Vaccination with recombinant whole heavy chain fragments of clostridium botulinum type C and D neurotoxins Clin. Diagn. Lab. Immunol. 11 2004 496 502
64. T.E. Rocke, M.D. Samuel, P.K. Swift, and G.S. Yarris Efficacy of a type C botulism vaccine in green-winged teal J. Wildl. Dis. 36 2000 489 493
65. R.L. Whalen, D.J. Dempsey, L.M. Thompson, K. Bucknell, R. Kunitomo, Y. Okazaki, and H. Harasaki Microencapsulated vaccines to provide prolonged immunity with a single administration ASAIO J. 42 1996 M649 M654
66. J.L. Holley, E.D. Williamson, J.E. Eyles, H.O. Alpar, and R.W. Titball Use of poly-l-lactide microspheres for the delivery of a Clostridium botulinum type F subunit vaccine Proceedings of the 10th European Workshop Conference on Bacterial Protein Toxins, Bohon (Belgium) 2001
67. L.G. Doan Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review J. Toxicol., Clin. Toxicol. 42 2004 201 208
68. M.J. Lord, N.A. Jolliffe, C.J. Marsden, C.S. Pateman, D.C. Smith, R.A. Spooner, P.D. Watson, and L.M. Roberts Ricin. Mechanisms of cytotoxicity Toxic. Rev. 22 2003 53 64
69. C.J. Marsden, S. Knight, D.C. Smith, P.J. Day, L.M. Roberts, G.J. Phillips, and J.M. Lord Insertional mutagenesis of ricin a chain: a novel route to an anti-ricin vaccine Vaccine 22 2004 2800 2805
70. M.A. Olson, J.H. Carra, V. Roxas-Duncan, R.W. Wannemacher, L.A. Smith, and C.B. Millard Finding a new vaccine in the ricin protein fold Protein Eng. Des., Sel. 17 2004 391 397
71. J.E. Smallshaw, A. Firan, J.R. Fulmer, S.L. Ruback, V. Ghetie, and E.S. Vitetta A novel recombinant vaccine which protects mice against ricin intoxication Vaccine 20 2002 3422 3427
72. M. Kende, C. Yan, J. Hewetson, M.A. Frick, W.L. Rill, and R. Tammariello Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge Vaccine 20 2002 1681 1691
73. C. Yan, W.L. Rill, R. Malli, J. Hewetson, H. Naseem, R. Tammariello, and M. Kende Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres Vaccine 14 1996 1031 1038
74. C. Yan, W.L. Rill, R. Malli, J. Hewetson, R. Tammariello, and M. Kende Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers Vaccine 13 1995 645 651
75. G.D. Griffiths, S.C. Bailey, J.L. Hambrook, and M.P. Keyte Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations Vaccine 16 1998 530 535
76. G.D. Griffiths, G.J. Phillips, and S.C. Bailey Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation Vaccine 17 1999 2562 2568
77. R.O. Baker, M. Bray, and J.W. Huggins Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections Antivir. Res. 57 2003 13 23
78. F. Fenner, D.A. Henderson, I. Arita, Z. Jezek, and I.D. Ladnyi Smallpox and Its Eradication 1988 World Health Organization Geneva 92 4 156110 6
79. J.G. Breman, and D.A. Henderson Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism N. Engl. J. Med. 339 1998 556 559
80. M. Bray, and M. Buller Looking back at smallpox Clin. Infect. Dis. 38 2004 882 889
81. D.F. Smee, and R.W. Sidwell A review of compounds exhibiting anti-orthopoxvirus activity in animal models Antivir. Res. 57 2003 41 52
82. G.A. Poland, and J.M. Neff Smallpox vaccine: problems and prospects Immunol. Allergy Clin. North Am. 23 2003 731 743
83. D.J. Pulford, A. Gates, S.H. Bridge, J.H. Robinson, and D. Ulaeto Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge Vaccine 22 2004 3358 3366
84. D.F. Smee, K.W. Bailey, and R.W. Sidwell Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir Antivir. Chem. Chemother. 12 2001 71 76
85. + T-cell peptide epitope of vaccinia and variola viruses J. Virol. 78 2004 7052 7060
86. M. Bray Defense against filoviruses used as biological weapons Antivir. Res. 57 2003 53 60
87. M. Bray, and J. Paragas Experimental therapy of filovirus infections Antivir. Res. 54 2002 1 17
88. A.M. Casillas, A.M. Nyamathi, A. Sosa, C.L. Wilder, and H. Sands A current review of ebola virus: pathogenesis, clinical presentation, and diagnostic assessment Biol. Res. Nurs. 4 2003 268 275
89. M. Bray, K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever J. Infect. Dis. 178 1998 651 661
90. J.A. Wilson, M. Hevey, R. Bakken, S. Guest, M. Bray, A.L. Schmaljohn, and M.K. Hart Epitopes involved in antibody-mediated protection from ebola virus Science 287 2000 1664 1666
91. M. Hevey, D. Negley, L. VanderZanden, R.F. Tammariello, J. Geisbert, C. Schmaljohn, J.F. Smith, P.B. Jahrling, and A.L. Schmaljohn Marburg virus vaccines: comparing classical and new approaches Vaccine 20 2001 586 593
92. K.L. Warfield, D.L. Swenson, D.L. Negley, A.L. Schmaljohn, M.J. Aman, and S. Bavari Marburg virus-like particles protect guinea pigs from lethal marburg virus infection Vaccine 22 2004 3495 3502
93. K.L. Warfield, C.M. Bosio, B.C. Welcher, E.M. Deal, M. Mohamadzadeh, A. Schmaljohn, M.J. Aman, and S. Bavari Ebola virus-like particles protect from lethal ebola virus infection Proc. Natl. Acad. Sci. U. S. A. 100 2003 15889 15894
94. M. Rao, G.R. Matyas, F. Grieder, K. Anderson, P.B. Jahrling, and C.R. Alving Cytotoxic T lymphocytes to ebola zaire virus are induced in mice by immunization with liposomes containing lipid A Vaccine 17 1999 2991 2998
95. M. Rao, M. Bray, C.R. Alving, P. Jahrling, and G.R. Matyas Induction of immune responses in mice and monkeys to ebola virus after immunization with liposome-encapsulated irradiated ebola virus: protection in mice requires CD4+ T cells J. Virol. 76 2002 9176 9185
96. D.J. Brayden Oral vaccination in man using antigens in particles: current status Eur. J. Pharm. Sci. 14 2001 183 189
97. J.A. Bellanti, B.J. Zeligs, J.M. de Inocencio, B.M. Omidvar, J. Omidvar, and M. Awasum Alternative routes of immunization for prevention of infectious diseases: a new paradigm for the 21st century Allergy Asthma Proc. 22 2001 173 176
98. N.W. Thomas, P.G. Jenkins, K.A. Howard, M.W. Smith, E.C. Lavelle, J. Holland, and S.S. Davis Particle uptake and translocation across epithelial membranes J. Anat. 189 1996 487 490
99. H. Critchley, S.S. Davis, N.F. Farraj, and L. Illum Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system J. Pharm. Pharmacol. 46 1994 651 656
100. M. Singh, M. Briones, and D.T. O'Hagan A novel bioadhesive intranasal delivery system for inactivated influenza vaccines J. Control. Release 70 2001 267 276
101. J. Eyles, O. Alpar, W.N. Field, D.A. Lewis, and M. Keswick The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat J. Pharm. Pharmacol. 47 1995 561 565
102. H.O. Alpar, W.N. Field, R. Hyde, and D.A. Lewis The transport of microspheres from the gastro-intestinal tract to inflammatory air pouches in the rat J. Pharm. Pharmacol. 41 1989 194 196
103. D.J. Brayden, and D.J. O'Mahony Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines Pharm. Sci. Technol. Today 1 1998 291 299
104. J.E. Eyles, V.W. Bramwell, E.D. Williamson, and H.O. Alpar Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration Vaccine 19 2001 4732 4742
105. S.S. Jadhav, and S. Gairola Composition of acellular pertussis and combination vaccines: a general review Biologicals 27 1999 105 110
106. D.T. Dennis, T.V. Inglesby, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, A.M. Friedlander, J. Hauer, M. Layton, S.R. Lillibridge, J.E. McDade, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, and K. Tonat Tularemia as a biological weapon: medical and public health management JAMA 285 2001 2763 2773
107. P.C. Turnbull Anthrax vaccines: past, present and future Vaccine 9 1991 533 539
108. T.V. Inglesby, T. O'Toole, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M.T. Osterholm, G. Parker, T.M. Perl, P.K. Russell, and K. Tonat Anthrax as a biological weapon, 2002: updated recommendations for management JAMA 287 2002 2236 2252
109. M.L. Pitt, S. Little, B.E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A.M. Friedlander In vitro correlate of immunity in an animal model of inhalational anthrax J. Appl. Microbiol. 87 1999 304
110. J.E. Eyles, G.J.E. Sharp, E.D. Williamson, I.D. Spiers, and H.O. Alpar Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse Vaccine 16 1998 698 707
111. T.V. Inglesby, D.T. Dennis, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, A.M. Friedlander, J. Hauer, J.F. Koerner, M. Layton, J. McDade, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, M. Schoch-Spana, and K. Tonat Plague as a biological weapon: medical and public health management. Working group on civilian biodefense JAMA 283 2000 2281 2290
112. H.O. Alpar, J.E. Eyles, E.D. Williamson, and S. Somavarapu Intranasal vaccination against plague, tetanus and diphtheria Adv. Drug Deliv. Rev. 51 2001 173 201
113. K.F. Griffin, J.E. Eyles, I.D. Spiers, H.O. Alpar, and E.D. Williamson Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-[gamma] or IL-4, but not IL-6 Vaccine 20 2002 3650 3657
114. H.P. Hughes Cytokine adjuvants: lessons from the past-guidelines for the future? Vet. Immunol. Immunopathol. 63 1998 131 138
115. K.F. Griffin, B.R. Conway, H.O. Alpar, and E.D. Williamson Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-[gamma]: effect of dose and formulation Vaccine 16 1998 517 521